Literature DB >> 36050548

The genomic landscape of pediatric acute lymphoblastic leukemia.

Samuel W Brady1, Kathryn G Roberts2, Zhaohui Gu3, Lei Shi4, Stanley Pounds4, Deqing Pei4, Cheng Cheng4, Yunfeng Dai5, Meenakshi Devidas6, Chunxu Qu2, Ashley N Hill2, Debbie Payne-Turner2, Xiaotu Ma1, Ilaria Iacobucci2, Pradyuamna Baviskar2, Lei Wei1, Sasi Arunachalam1, Kohei Hagiwara1, Yanling Liu1, Diane A Flasch1, Yu Liu1, Matthew Parker1, Xiaolong Chen1, Abdelrahman H Elsayed2,4, Omkar Pathak1, Yongjin Li1, Yiping Fan1, J Robert Michael1, Michael Rusch1, Mark R Wilkinson1, Scott Foy1, Dale J Hedges1, Scott Newman1, Xin Zhou1, Jian Wang1, Colleen Reilly1, Edgar Sioson1, Stephen V Rice1, Victor Pastor Loyola1, Gang Wu7, Evadnie Rampersaud7, Shalini C Reshmi8, Julie Gastier-Foster9, Jaime M Guidry Auvil10,11, Patee Gesuwan10, Malcolm A Smith12, Naomi Winick13, Andrew J Carroll14, Nyla A Heerema15, Richard C Harvey16, Cheryl L Willman17, Eric Larsen18, Elizabeth A Raetz19, Michael J Borowitz20, Brent L Wood21, William L Carroll19, Patrick A Zweidler-McKay22, Karen R Rabin9, Leonard A Mattano23, Kelly W Maloney24, Stuart S Winter25, Michael J Burke26, Wanda Salzer27, Kimberly P Dunsmore28, Anne L Angiolillo29, Kristine R Crews30, James R Downing2, Sima Jeha31, Ching-Hon Pui31, William E Evans30, Jun J Yang30, Mary V Relling30, Daniela S Gerhard10, Mignon L Loh32, Stephen P Hunger33, Jinghui Zhang34, Charles G Mullighan35.   

Abstract

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Here, using whole-genome, exome and transcriptome sequencing of 2,754 childhood patients with ALL, we find that, despite a generally low mutation burden, ALL cases harbor a median of four putative somatic driver alterations per sample, with 376 putative driver genes identified varying in prevalence across ALL subtypes. Most samples harbor at least one rare gene alteration, including 70 putative cancer driver genes associated with ubiquitination, SUMOylation, noncoding transcripts and other functions. In hyperdiploid B-ALL, chromosomal gains are acquired early and synchronously before ultraviolet-induced mutation. By contrast, ultraviolet-induced mutations precede chromosomal gains in B-ALL cases with intrachromosomal amplification of chromosome 21. We also demonstrate the prognostic significance of genetic alterations within subtypes. Intriguingly, DUX4- and KMT2A-rearranged subtypes separate into CEBPA/FLT3- or NFATC4-expressing subgroups with potential clinical implications. Together, these results deepen understanding of the ALL genomic landscape and associated outcomes.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Year:  2022        PMID: 36050548     DOI: 10.1038/s41588-022-01159-z

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   41.307


  82 in total

1.  A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia.

Authors:  Y Gocho; N Kiyokawa; H Ichikawa; K Nakabayashi; T Osumi; T Ishibashi; H Ueno; K Terada; K Oboki; H Sakamoto; Y Shioda; M Imai; Y Noguchi; Y Arakawa; Y Kojima; D Toyama; K Hata; T Yoshida; K Matsumoto; M Kato; T Fukushima; K Koh; A Manabe; A Ohara
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

Review 2.  New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Henrik Lilljebjörn; Thoas Fioretos
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

3.  Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.

Authors:  Jinghui Zhang; Kelly McCastlain; Hiroki Yoshihara; Beisi Xu; Yunchao Chang; Michelle L Churchman; Gang Wu; Yongjin Li; Lei Wei; Ilaria Iacobucci; Yu Liu; Chunxu Qu; Ji Wen; Michael Edmonson; Debbie Payne-Turner; Kerstin B Kaufmann; Shin-Ichiro Takayanagi; Erno Wienholds; Esmé Waanders; Panagiotis Ntziachristos; Sofia Bakogianni; Jingjing Wang; Iannis Aifantis; Kathryn G Roberts; Jing Ma; Guangchun Song; John Easton; Heather L Mulder; Xiang Chen; Scott Newman; Xiaotu Ma; Michael Rusch; Pankaj Gupta; Kristy Boggs; Bhavin Vadodaria; James Dalton; Yanling Liu; Marcus L Valentine; Li Ding; Charles Lu; Robert S Fulton; Lucinda Fulton; Yashodhan Tabib; Kerri Ochoa; Meenakshi Devidas; Deqing Pei; Cheng Cheng; Jun Yang; William E Evans; Mary V Relling; Ching-Hon Pui; Sima Jeha; Richard C Harvey; I-Ming L Chen; Cheryl L Willman; Guido Marcucci; Clara D Bloomfield; Jessica Kohlschmidt; Krzysztof Mrózek; Elisabeth Paietta; Martin S Tallman; Wendy Stock; Matthew C Foster; Janis Racevskis; Jacob M Rowe; Selina Luger; Steven M Kornblau; Sheila A Shurtleff; Susana C Raimondi; Elaine R Mardis; Richard K Wilson; John E Dick; Stephen P Hunger; Mignon L Loh; James R Downing; Charles G Mullighan
Journal:  Nat Genet       Date:  2016-10-24       Impact factor: 38.330

Review 4.  Why and how to treat Ph-like ALL?

Authors:  Kathryn G Roberts
Journal:  Best Pract Res Clin Haematol       Date:  2018-09-20       Impact factor: 3.020

5.  Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Xiaoping Su; Jinghui Zhang; Ina Radtke; Letha A A Phillips; Christopher B Miller; Jing Ma; Wei Liu; Cheng Cheng; Brenda A Schulman; Richard C Harvey; I-Ming Chen; Robert J Clifford; William L Carroll; Gregory Reaman; W Paul Bowman; Meenakshi Devidas; Daniela S Gerhard; Wenjian Yang; Mary V Relling; Sheila A Shurtleff; Dario Campana; Michael J Borowitz; Ching-Hon Pui; Malcolm Smith; Stephen P Hunger; Cheryl L Willman; James R Downing
Journal:  N Engl J Med       Date:  2009-01-07       Impact factor: 91.245

Review 6.  Philadelphia chromosome-like acute lymphoblastic leukemia.

Authors:  Sarah K Tasian; Mignon L Loh; Stephen P Hunger
Journal:  Blood       Date:  2017-10-02       Impact factor: 22.113

7.  Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.

Authors:  Zhaohui Gu; Michelle Churchman; Kathryn Roberts; Yongjin Li; Yu Liu; Richard C Harvey; Kelly McCastlain; Shalini C Reshmi; Debbie Payne-Turner; Ilaria Iacobucci; Ying Shao; I-Ming Chen; Marcus Valentine; Deqing Pei; Karen L Mungall; Andrew J Mungall; Yussanne Ma; Richard Moore; Marco Marra; Eileen Stonerock; Julie M Gastier-Foster; Meenakshi Devidas; Yunfeng Dai; Brent Wood; Michael Borowitz; Eric E Larsen; Kelly Maloney; Leonard A Mattano; Anne Angiolillo; Wanda L Salzer; Michael J Burke; Francesca Gianni; Orietta Spinelli; Jerald P Radich; Mark D Minden; Anthony V Moorman; Bella Patel; Adele K Fielding; Jacob M Rowe; Selina M Luger; Ravi Bhatia; Ibrahim Aldoss; Stephen J Forman; Jessica Kohlschmidt; Krzysztof Mrózek; Guido Marcucci; Clara D Bloomfield; Wendy Stock; Steven Kornblau; Hagop M Kantarjian; Marina Konopleva; Elisabeth Paietta; Cheryl L Willman; Mignon L Loh; Stephen P Hunger; Charles G Mullighan
Journal:  Nat Commun       Date:  2016-11-08       Impact factor: 14.919

Review 8.  The Biology of B-Progenitor Acute Lymphoblastic Leukemia.

Authors:  Kathryn G Roberts; Charles G Mullighan
Journal:  Cold Spring Harb Perspect Med       Date:  2020-07-01       Impact factor: 5.159

9.  Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia.

Authors:  Henrik Lilljebjörn; Rasmus Henningsson; Axel Hyrenius-Wittsten; Linda Olsson; Christina Orsmark-Pietras; Sofia von Palffy; Maria Askmyr; Marianne Rissler; Martin Schrappe; Gunnar Cario; Anders Castor; Cornelis J H Pronk; Mikael Behrendtz; Felix Mitelman; Bertil Johansson; Kajsa Paulsson; Anna K Andersson; Magnus Fontes; Thoas Fioretos
Journal:  Nat Commun       Date:  2016-06-06       Impact factor: 14.919

View more
  2 in total

Review 1.  Hyperdiploidy: the longest known, most prevalent, and most enigmatic form of acute lymphoblastic leukemia in children.

Authors:  Oskar A Haas; Arndt Borkhardt
Journal:  Leukemia       Date:  2022-10-20       Impact factor: 12.883

2.  Normal and Aberrant TALE-Class Homeobox Gene Activities in Pro-B-Cells and B-Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Stefan Nagel; Corinna Meyer
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.